Growth in the global transfection technologies market will be driven by emerging methods and the increasing prevalence of chronic diseases over the next five years.
List view / Grid view
22 October 2015 | By Laura Juckem, PhD, R&D Group Leader at Mirus Bio
Laura Juckem, PhD, R&D Group Leader at Mirus Bio, discusses the company’s systems for optimising suspension Chinese hamster ovary (CHO) cells...
Whitepaper: Development and optimization of CHOgro® transient expression technologies for high titer antibody production in suspension CHO cells
During early stage drug development, quickly obtaining relevant candidate proteins through transient transfection can accelerate drug discovery.